Why your doctor may choose DOXIL®
DOXIL®, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have tried at least 1 prior therapy. Treatment is continued until the cancer worsens or the side effects become intolerable.
Multiple myeloma is a type of blood cancer that develops in the plasma cells, which are found in the bone marrow. Plasma cells are a type of white blood cell that help your immune system fight infections. The cancerous plasma cells produce abnormal proteins that can damage the kidneys and weaken the immune system. These cancerous cells replace normal cells with tumors, usually in the bone marrow. Increases in diseased cells can cause bone damage, resulting in bone pain or fractures. This disease may return after your first treatment and does not always respond to therapy. You and your doctor will discuss which treatment options are right for you.
Additional information about how DOXIL® works and about relapsed or refractory multiple myeloma
Talk with your team of healthcare professionals about your relapsed or refractory multiple myeloma and what to expect from treatment.
- The type of cancer recurrence you experience can affect the treatments available to you.
- The term "relapsed" describes cancer that returns after a period of improvement
- "Refractory" myelomas are not responsive to therapy
- DOXIL® is in the anthracycline drug group, which is widely used for a variety of cancers. Anthracyclines cause cancer cells to die by damaging their DNA.
- STEALTH® technology makes DOXIL® work differently by wrapping up the chemotherapy agent doxorubicin HCl in a protective layer. This makes it harder for the immune system to find and destroy the drug, so it stays active in your body longer. Once DOXIL® reaches cancer tissue, it is slowly released. However, DOXIL® can also affect normal tissue. If you have more questions about how DOXIL® is different from other anthracyclines, ask your team of healthcare professionals.